

**UCI Health**Chao Family  
Comprehensive Cancer Center

## Cancer Clinical Trials

These featured cancer clinical trials are currently open at the UCI Chao Family Comprehensive Center.

To refer a patient or get more information about a clinical trial, click on the principal investigator's name to send an email. You may also contact us at [ucstudy@uci.edu](mailto:ucstudy@uci.edu) or [877-UC-Study](tel:877-UC-Study). To search all cancer clinical trials now available at UCI Health, visit [cancer.uci.edu/cancertrials](https://cancer.uci.edu/cancertrials)

### COVID-19

NCI COVID-19 in cancer patients study (NCCAPS): A longitudinal natural history study (NCICOVID)

*Principal investigator: Susan O'Brien, MD*

### Brain/Nervous System

A randomized, double-blind, placebo-controlled Phase 3 study of enzastaurin added to temozolomide during and following radiation therapy in newly diagnosed glioblastoma patients who possess the novel genomic biomarker DGM1. (DB102-01/UCI 19-99)

*Principal investigator: Daniela Bota, MD*

Phase 2 single-arm study of NOVOTTF-200A in bevacizumab-naive subjects with recurrent grade III malignant astrocytoma (novottf-200a/UCI 16-56)

*Principal investigator: Daniela Bota, MD*

### Breast

A Phase 2 open-label trial of neo-adjuvant abemaciclib with fulvestrant in patients who develop localized recurrence while on adjuvant endocrine therapy with molecular evidence of endocrine resistance (13Y-US-X013/UCI 18-79)

*Principal Investigator: Ritesh Parajuli, MD*

A randomized Phase 1/2 trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone-receptor positive, HER2-negative metastatic breast cancer (FAC vs FA) (ETCTN 10287)

*Principal Investigator: Ritesh Parajuli, MD*

## **Gastrointestinal**

A Phase 2a multicenter, open-label study of DKN-01 in combination with tislelizumab and chemotherapy as first-line or second-line therapy in adult patients with inoperable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (DisTinGuish) (DEK-DKK1-P205/UCI 20-63)

*Principal Investigator: Farshid Dayyani, MD*

A Phase 2 single-arm study of M6620 in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer (ETCTN 10211)

*Principal Investigator: Farshid Dayyani, MD*

## **Genitourinary**

A Phase 2 study of AZD1775 in SETD2-deficient advanced solid tumor malignancies (ETCTN 10170)

*Principal Investigator, Arash Rezazadeh Kalebasty, MD*

A Phase 2 single arm study of CG0070 combined with pembrolizumab in patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guerin (BCG) (CG2003C/UCI 20-91)

*Principal investigator: Edward Uchio, MD*

## **Gynecologic Oncology**

A randomized Phase 2/3 study of pegylated liposomal doxorubicin and CTEP-supplied atezolizumab versus pegylated liposomal doxorubicin/bevacizumab and CTEP-supplied atezolizumab versus pegylated liposomal doxorubicin/bevacizumab in platinum resistant ovarian cancer (NRG-GY009)

*Principal investigator: Krishnansu Tewari, MD*

A randomized Phase 2 study of bevacizumab and either weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or platinum refractory ovarian cancer (ETCTN 10150)

*Principal investigator: Jill Tseng, MD*

## Hepatobiliary

A Phase 1/2 study of M3814 (peposertib) in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma (ETCTN 10366)

*Principal Investigator: Farshid Dayyani, MD*

A Phase 2 study of XL184 (cabozantinib) in combination with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN 10315)

*Principal Investigator: Farshid Dayyani, MD*

## Hematologic Malignancies

Phase 3 open-label study on zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation (BGB-3111-306/UCI 19-58)

*Principal investigator: Lauren Pinter-Brown, MD*

A randomized, open-label, controlled Phase 2 study of pevonedistat, venetoclax and azacitidine versus venetoclax plus azacitidine in adults with newly diagnosed acute myeloid leukemia who are not candidates for intensive chemotherapy (Pevonedistat-2002/UCI 20-30)

*Principal Investigator: Elizabeth Brém, MD*

## Lung

A Phase 1/2 open-label, two-part, multicenter study to assess the safety, tolerability, pharmacokinetics and antitumor activity of BDTX-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies (BDTX-189-01/UCI 19-121)

*Principal Investigator: Viola Zhu, MD*

A Phase 1 open-label, multi-center, first-in-humans study of the safety, tolerability, pharmacokinetics and anti-tumor activity of TPX-0022, a novel Met/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in Met (TPX-0022-01/UCI 19-57)

*Principal Investigator: Viola Zhu, MD*

## Skin

Phase 1/2 study of dabrafenib, trametinib and navitoclax in BRAF mutant melanoma (Phase 1 and 2) and other solid tumors (Phase 1 Only) (ETCTN 9466)

*Principal investigator: Jennifer Valerin, MD*

A Phase 1b/2 study of cavrotolimod combined with pembrolizumab or cemiplimab in patients with advanced solid tumors (AST-008-102/UCI 19-91)

*Principal investigator: Ling Gao, MD*

## Neuroendocrine

A Phase 2 study of XL184 (cabozantinib) in combination with nivolumab and ipilimumab for the treatment of poorly differentiated neuroendocrine carcinomas (ETCTN 10315)

*Principal Investigator: Farshid Dayyani, MD*

## Head and Neck

Randomized Phase 2 and Phase 3 studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) (NRG-HN001)

*Principal Investigator: Rupali Nabar, MD*



As an NCI-designated comprehensive cancer center, the UCI Chao Family Comprehensive Cancer Center conducts many clinical trials. By participating in a clinical trial, your patients have access to leading-edge treatments and therapies long before they are available to the general public. According to the National Comprehensive Cancer Network (NCCN) guidelines, the best management for any cancer patient is on a clinical trial.

**UCI Health** | Chao Family Comprehensive Cancer Center | **NCI** National Cancer Institute  
A Division of the National Institutes of Health

UCI Medical Center | 101 The City Drive South | Orange, CA 92868

CS 3234 12/20